Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
172,900 ^KRW	-2.37%		-3.68%	-14.19%

Apr. 17	Celltrion, Inc. announces an Equity Buyback for 436,047 shares.	CI
Apr. 17	Celltrion, Inc. authorizes a Buyback Plan.	CI

Celltrion Files IND With FDA For Adalimumab Biosimilar

August 09, 2022 at 06:10 am EDT

As reported by Pulse and DailyPharm Korea, Celltrion recently filed an Investigational New Drug (IND) application with the FDA for a global Phase 3 clinical trial aimed at demonstrating its biosimilar's (YUFLYMA) interchangeability with HUMIRA (adalimumab). The trial will evaluate the pharmacokinetics, efficacy, and safety of YUFLYMA in 366 patients with plaque psoriasis. Celltrion submitted its application to the FDA for approval of YUFLYMA in November 2020, and plans to launch YUFLYMA in the United States in 2023.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Sean Anderson
Goodwin Procter LLP
601 South Figueroa Street
Suite 4100
Los Angeles
CA 90017
UNITED STATES
Tel: 212813 8800
E-mail: JScalzi@goodwinlaw.com
URL: www.goodwinprocter.com

Latest news about Celltrion, Inc.

Celltrion, Inc. announces an Equity Buyback for 436,047 shares.	Apr. 17	CI
Celltrion, Inc. authorizes a Buyback Plan.	Apr. 16	CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 5, 2024.	Mar. 28	CI
Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million.	Mar. 25	CI
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
South Korean Shares Close Higher on Tech Gains; Celltrion Shares Add 1% on Zymfentra Launch in the US	Mar. 18	MT
Celltrion's Autoimmune Disease Treatment Hits US Markets	Mar. 18	MT
South Korean Shares Slightly Slip as Investors Seek Cues on Future Rate Direction from US Fed	Mar. 06	MT
Celltrion Announces 75 Billion Won Share Buyback Plan	Mar. 06	MT
Celltrion, Inc. announces an Equity Buyback for 425,895 shares.	Mar. 04	CI
Celltrion, Inc. authorizes a Buyback Plan.	Mar. 04	CI
South Korean Shares Dip on Tech, Pharma Losses; Celltrion Sheds 5% on Lackluster Q4 Earnings	Feb. 29	MT
Celltrion's Net Profit Nosedives 98.5% in Q4 2023 as Revenue Declines 25%	Feb. 29	MT
Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease	Feb. 23	CI
South Korean Shares Close Lower on Hotter-Than-Expected US Inflation Data	Feb. 14	MT
Celltrion Pursues EMA Approval for Actemra Biosimilar	Feb. 14	MT
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates	Jan. 23	CI
Celltrion Strikes Key Anti-Cancer Treatment Deals Across Europe	Jan. 19	MT
Celltrion Holdings Actively Pursuing Nasdaq Listing	Jan. 16	MT
Celltrion Seeks US Interchangeability Designation for Autoimmune Disease Biosimilar	Jan. 10	MT
Celltrion Announces Cancellation of Over 1% of Outstanding Shares	Jan. 08	MT
South Korean Shares Decline After Latest Fed Minutes Indicate Continuation of High-Interest Rates	Jan. 04	MT
South Korean shares fall for second day after US Fed minutes	Jan. 03	RE
S.Korean shares fall after Fed minutes; biopharma leads declines	Jan. 04	RE
Celltrion Group Plans $160 Million Divestment of Primary Care Business Rights in Asia-Pacific	Jan. 03	MT

Chart Celltrion, Inc.

Duration

Period

More charts

Company Profile

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Celltrion, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

177,100 KRW

Average target price

227,765 KRW

Spread / Average Target

+28.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELLTRION, INC.	-14.19%	26.67B
IQVIA HOLDINGS INC.	-1.99%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.95%	39.05B
ICON PUBLIC LIMITED COMPANY	+1.52%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.06%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.13%	11.68B
MEDPACE HOLDINGS, INC.	+20.79%	11.6B
UNITED THERAPEUTICS CORPORATION	+6.91%	11.15B
BIO-TECHNE CORPORATION	-19.23%	9.78B

Other Biotechnology & Medical Research